The news directly pertains to Avid Bioservices as RBC Capital has lowered its price target for the company. However, the Outperform rating is maintained, indicating that the analyst still expects the company to outperform the market. This could have a neutral impact on the stock price in the short term as the lowered price target might be offset by the maintained positive rating.